Burns D, Kula J, Marshall S, Ashworth E, Ornelas M. Best practice approach to successful conversion of fosaprepitant to aprepitant IV in a large multisite community oncology infusion center: A retrospective analysis. Advances in Therapy. May 23, 2020 [Epub ahead of print]. doi.org/10.1007/s12325-020-01377-z.
Perry TS, Dickson N, Patton JF. Safety of antiemetic prophylaxis with HTX-019 as a 30-min infusion in patients with cancer: a retrospective study [published online ahead of print January 27, 2020]. Future Oncol. doi: 10.2217/fon-2019-0835.
Ottoboni T, Keller MR, Cravets M, Clendeninn N, Quart B. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation. Drug Des Devel Ther. 2018;12:429-435.
Goudra B, Singh N, Xue L, Goyal A, Gouda D, Singh PM. Efficacy of new long acting bupivacaine HTX 011 in providing pain relief for patients undergoing elective surgery – a meta analysis of prospective randomized controlled trials. Anesth Essays Res. 2020;14(2):288-294.
Singla N, Winkle P, Bertoch T, Hu J, Beaton A, Redan J. Opiod-free recovery after herniorrhaphy with HTX-011 as the foundation of a multimodal analgesic regimen [published online ahead of print September 14, 2020]. Surgery. doi: 10.1016/j.surg.2020.06.036.
Lachiewicz PF, Lee G-C, Pollak RA, Leiman DG, Hu J, Sah AP. HTX-011 reduced pain and opioid use after primary total knee arthroplasty: results of a randomized phase 2b trial [Published ahead of print on May 27, 2020]. J Arthroplasty. doi: https://doi.org/10.1016/j.arth.2020.05.044.
Ottoboni T, Quart B, Pawasauskas J, Dasta JF, Pollak RA, Viscusi ER. Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain [published online ahead of print December 16, 2019]. Reg Anesth Pain Med. doi: 10.1136/rapm-2019-100714.
Viscusi E, Minkowitz H, Winkle P, Ramamoorthy S, Hu J, Singla N. HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study [published online ahead of print August 19, 2019]. Hernia. doi: 10.1007/s10029-019-02023-6.
Viscusi E, Gimbel JS, Pollack RA, Hu J, Lee G-C. HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in bunionectomy: Phase 3 results from the randomized EPOCH 1 study. Reg Anesth Pain Med. 2019;44:700-706.
*ZYNRELEF is the approved trade name for HTX-011 in the European Union.
Schwartzberg LS, Marks SM, Gabrail NY, Geller RB, Kish J. Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting. J Comp Eff Res. 2019;8(9):657-670.
Smith C, Smith M, Cunningham R, Davis S. Recent advances in antiemetics: New formulations of 5-HT3 receptor antagonists. Cancer Nursing. January 25, 2019 [Epub ahead of print]. doi: 10.1097/NCC.0000000000000694.
Vacirca J, Caruana D, Calcanes G, Mosier M, Boccia R, McBride A. Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron. Future Oncol. 2018;14(14):1387-1396.
Schnadig ID, Agajanian R, Dakhil C, Gabrail N, Vacirca J, Taylor C, Wilks S, Braun E, Mosier MC, Geller RB, Schwartzberg L, Vogelzang N. APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the phase III randomized MAGIC trial. Cancer Manag Res. 2017;9:179-187.
Schwartzberg L, Mosier M, Geller RB, Klepper MJ, Schnadig I, Vogelzang NJ. APF530 for nausea and vomiting prevention following cisplatin: phase 3 MAGIC trial analysis. J Community Support Oncol. 2017;15(2):82-88.
Schnadig ID, Agajanian R, Dakhil C, Gabrail NY, Smith RE Jr, Taylor C, Wilks ST, Schwartzberg LS, Cooper W, Mosier MC, Payne JY, Klepper MJ, Vacirca JL. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. Future Oncol. 2016;12(12):1469-1481.
Boccia R, O’Boyle E, Cooper W. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy. BMC Cancer. 2016;16(1):166.
Raftopoulos H, Boccia R, Cooper W, O’Boyle E, Gralla RJ. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria. Future Oncol. 2015;11(18):2541-2551.
Boccia R, Cooper W, O’Boyle E. Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy. J Community Support Oncol. 2015;3(2):38-46.
Raftopoulos H, Cooper W, O’Boyle E, Gabrail N, Boccia R, Gralla RJ. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer. 2015;23(3):723-732.
Gabrail N, Yanagihara R, Spaczyński M, Cooper W, O’Boyle E, Smith C, Boccia R. Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two phase 2 trials. Cancer Manag Res. 2015;7:83-92.
Mason JW, Moon TE, O’Boyle E, Dietz A. A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. Cancer Manag Res. 2014;6:181-190.